These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

528 related articles for article (PubMed ID: 28870957)

  • 1. Comparing the Efficacy of DeVIC Therapy and High-dose Methotrexate Monotherapy with Whole-brain Radiation Therapy for Newly-diagnosed Primary Central Nervous System Lymphoma: A Single Institution Study.
    Chalise L; Motomura K; Ohka F; Hirano M; Hara M; Nishimura Y; Natsume A; Wakabayashi T
    Anticancer Res; 2017 Sep; 37(9):5215-5223. PubMed ID: 28870957
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term survival in patients with newly diagnosed primary central nervous system lymphoma treated with dexamethasone, etoposide, ifosfamide and carboplatin chemotherapy and whole-brain radiation therapy.
    Motomura K; Natsume A; Fujii M; Ito M; Momota H; Wakabayashi T
    Leuk Lymphoma; 2011 Nov; 52(11):2069-75. PubMed ID: 21745167
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High-dose methotrexate with or without whole brain radiotherapy for primary CNS lymphoma (G-PCNSL-SG-1): a phase 3, randomised, non-inferiority trial.
    Thiel E; Korfel A; Martus P; Kanz L; Griesinger F; Rauch M; Röth A; Hertenstein B; von Toll T; Hundsberger T; Mergenthaler HG; Leithäuser M; Birnbaum T; Fischer L; Jahnke K; Herrlinger U; Plasswilm L; Nägele T; Pietsch T; Bamberg M; Weller M
    Lancet Oncol; 2010 Nov; 11(11):1036-47. PubMed ID: 20970380
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Therapeutic management of central nervous system lymphomas in a single hematological institute].
    Iványi JL; Marton E; Plander M; Gyánó G; Czumbil L; Tóth C
    Orv Hetil; 2009 Oct; 150(42):1937-44. PubMed ID: 19812012
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Primary central nervous system lymphoma: Phase I evaluation of infusional bromodeoxyuridine with whole brain accelerated fractionation radiation therapy after chemotherapy.
    Dabaja BS; McLaughlin P; Ha CS; Pro B; Meyers CA; Seabrooke LF; Wilder RB; Kyritsis AP; Preti HA; Yung WK; Levin V; Cabanillas F; Cox JD
    Cancer; 2003 Sep; 98(5):1021-8. PubMed ID: 12942571
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Outcome of patients with newly diagnosed primary CNS lymphoma after high-dose methotrexate followed by consolidation whole-brain radiotherapy and cytarabine: an 8-year cohort study.
    Piriyakhuntorn P; Rattanathammethee T; Hantrakool S; Chai-Adisaksopha C; Rattarittamrong E; Tantiworawit A; Norasetthada L
    Int J Clin Oncol; 2021 Oct; 26(10):1805-1811. PubMed ID: 34236556
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of chemotherapy additional to high-dose methotrexate for primary central nervous system lymphoma (PCNSL).
    Bergner N; Monsef I; Illerhaus G; Engert A; Skoetz N
    Cochrane Database Syst Rev; 2012 Nov; 11():CD009355. PubMed ID: 23152274
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High-dose methotrexate-based regimens and post-remission consolidation for treatment of newly diagnosed primary CNS lymphoma: meta-analysis of clinical trials.
    Yu J; Du H; Ye X; Zhang L; Xiao H
    Sci Rep; 2021 Jan; 11(1):2125. PubMed ID: 33483528
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-Term Evaluation of Combination Treatment of Single Agent HD-MTX Chemotherapy up to Three Cycles and Moderate Dose Whole Brain Irradiation for Primary CNS Lymphoma.
    Kobayashi H; Yamaguchi S; Motegi H; Kaneko S; Endou S; Onimaru R; Terasaka S; Houkin K
    J Chemother; 2019 Feb; 31(1):35-41. PubMed ID: 30773132
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reduced neurotoxicity with combined treatment of high-dose methotrexate, cyclophosphamide, doxorubicin, vincristine and prednisolone (M-CHOP) and deferred radiotherapy for primary central nervous system lymphoma.
    Ichikawa T; Kurozumi K; Michiue H; Ishida J; Maeda Y; Kondo E; Kawasaki A; Date I
    Clin Neurol Neurosurg; 2014 Dec; 127():106-11. PubMed ID: 25459253
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Partial-brain radiotherapy for primary central nervous system lymphoma: multi-institutional experience.
    Iwabuchi M; Shibamoto Y; Sugie C; Ayakawa S; Ogino H; Baba F
    J Radiat Res; 2016 Mar; 57(2):164-8. PubMed ID: 26661856
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Primary central nervous system lymphoma--a report of 32 cases with literature review].
    Yi JQ; Lin TY; He YJ; Huang HQ; Xia ZJ; Xia YF; Xu RH; Guo Y; Guan ZZ
    Ai Zheng; 2006 Apr; 25(4):476-80. PubMed ID: 16613684
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High-dose chemotherapy and autologous stem cell transplant compared with conventional chemotherapy for consolidation in newly diagnosed primary CNS lymphoma--a randomized phase III trial (MATRix).
    Schorb E; Finke J; Ferreri AJ; Ihorst G; Mikesch K; Kasenda B; Fritsch K; Fricker H; Burger E; Grishina O; Valk E; Zucca E; Illerhaus G
    BMC Cancer; 2016 Apr; 16():282. PubMed ID: 27098429
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Results of treatment of 112 cases of primary CNS lymphoma.
    Yamanaka R; Morii K; Shinbo Y; Homma J; Sano M; Tsuchiya N; Yajima N; Tamura T; Hondoh H; Takahashi H; Kakuma T; Tanaka R
    Jpn J Clin Oncol; 2008 May; 38(5):373-80. PubMed ID: 18413337
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cognitive functions in primary CNS lymphoma after single or combined modality regimens.
    Correa DD; Shi W; Abrey LE; Deangelis LM; Omuro AM; Deutsch MB; Thaler HT
    Neuro Oncol; 2012 Jan; 14(1):101-8. PubMed ID: 22013168
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase II trial of temozolomide plus concurrent whole-brain radiation followed by TNV regimen as adjuvant therapy for patients with newly diagnosed primary CNS lymphoma.
    Wang Y; Liu B; Xu D; Zhao H; Zhu Y; Xu J; Tao R
    Neurol India; 2013; 61(3):260-4. PubMed ID: 23860145
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High-dose chemotherapy with autologous stem-cell transplantation and hyperfractionated radiotherapy as first-line treatment of primary CNS lymphoma.
    Illerhaus G; Marks R; Ihorst G; Guttenberger R; Ostertag C; Derigs G; Frickhofen N; Feuerhake F; Volk B; Finke J
    J Clin Oncol; 2006 Aug; 24(24):3865-70. PubMed ID: 16864853
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A prospective cohort study of methotrexate plus idarubicin in newly diagnosed primary CNS lymphoma.
    Li Q; Ma Y; Lin Z; Ma J; Kang H; Zhang M; Xu H; Chen B
    J Neurooncol; 2023 May; 163(1):39-46. PubMed ID: 35733032
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Outcome of elderly patients with primary CNS lymphoma in the G-PCNSL-SG-1 trial.
    Roth P; Martus P; Kiewe P; Möhle R; Klasen H; Rauch M; Röth A; Kaun S; Thiel E; Korfel A; Weller M
    Neurology; 2012 Aug; 79(9):890-6. PubMed ID: 22895585
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High-dose methotrexate with or without rituximab in newly diagnosed primary CNS lymphoma.
    Holdhoff M; Ambady P; Abdelaziz A; Sarai G; Bonekamp D; Blakeley J; Grossman SA; Ye X
    Neurology; 2014 Jul; 83(3):235-9. PubMed ID: 24928128
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.